Biotricity (BTCY) Competitors $0.54 -0.05 (-8.47%) As of 03:17 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainSEC FilingsTrendsBuy This Stock BTCY vs. PYPD, SRTS, APT, GUTS, NMTC, ZYXI, NEPH, WOK, PSTV, and MODDShould you be buying Biotricity stock or one of its competitors? The main competitors of Biotricity include PolyPid (PYPD), Sensus Healthcare (SRTS), Alpha Pro Tech (APT), Fractyl Health (GUTS), NeuroOne Medical Technologies (NMTC), Zynex (ZYXI), Nephros (NEPH), WORK Medical Technology Group (WOK), Plus Therapeutics (PSTV), and Modular Medical (MODD). These companies are all part of the "medical equipment" industry. Biotricity vs. Its Competitors PolyPid Sensus Healthcare Alpha Pro Tech Fractyl Health NeuroOne Medical Technologies Zynex Nephros WORK Medical Technology Group Plus Therapeutics Modular Medical Biotricity (NASDAQ:BTCY) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Which has more volatility & risk, BTCY or PYPD? Biotricity has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Do analysts prefer BTCY or PYPD? PolyPid has a consensus price target of $12.40, indicating a potential upside of 272.37%. Given PolyPid's stronger consensus rating and higher probable upside, analysts plainly believe PolyPid is more favorable than Biotricity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00PolyPid 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is BTCY or PYPD more profitable? PolyPid has a net margin of 0.00% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets Biotricity-80.42% N/A -188.47% PolyPid N/A -453.95%-138.92% Do insiders and institutionals believe in BTCY or PYPD? 3.9% of Biotricity shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 10.1% of Biotricity shares are held by insiders. Comparatively, 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, BTCY or PYPD? Biotricity has higher revenue and earnings than PolyPid. Biotricity is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiotricity$12.06M1.20-$14.09M-$0.21-2.57PolyPidN/AN/A-$29.02M-$3.83-0.87 Does the media favor BTCY or PYPD? In the previous week, PolyPid had 5 more articles in the media than Biotricity. MarketBeat recorded 5 mentions for PolyPid and 0 mentions for Biotricity. PolyPid's average media sentiment score of 0.92 beat Biotricity's score of 0.00 indicating that PolyPid is being referred to more favorably in the news media. Company Overall Sentiment Biotricity Neutral PolyPid Positive SummaryPolyPid beats Biotricity on 11 of the 16 factors compared between the two stocks. Get Biotricity News Delivered to You Automatically Sign up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTCY vs. The Competition Export to ExcelMetricBiotricitySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.43M$71.16M$5.70B$10.42BDividend YieldN/AN/A5.78%4.69%P/E Ratio-0.5010.5475.6626.39Price / Sales1.2030.11540.28125.20Price / CashN/A18.4125.6730.68Price / Book-0.4216.6612.826.40Net Income-$14.09M-$26.73M$3.29B$276.69M7 Day Performance-12.15%-0.76%1.12%-0.28%1 Month PerformanceN/A2.09%4.53%6.69%1 Year Performance116.00%69.77%67.99%27.62% Biotricity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTCYBiotricityN/A$0.54-8.5%N/A+136.0%$14.43M$12.06M-0.5040PYPDPolyPid3.259 of 5 stars$3.52+2.2%$12.40+252.8%-7.7%$54.54MN/A-0.9080Analyst UpgradeSRTSSensus Healthcare2.5996 of 5 stars$3.19+1.3%$8.00+150.7%-47.3%$52.61M$41.81M-53.3340Positive NewsGap UpAPTAlpha Pro Tech1.5298 of 5 stars$4.78+0.1%N/A-14.4%$50.01M$58.56M12.91120GUTSFractyl Health2.4562 of 5 stars$0.99-0.2%$7.15+622.2%-47.7%$49.87M$90K-0.48102Analyst ForecastGap UpNMTCNeuroOne Medical Technologies3.0536 of 5 stars$0.99+4.4%$2.23+125.9%-9.9%$49.25M$3.45M-6.5720Positive NewsGap UpZYXIZynex2.25 of 5 stars$1.56-1.6%$4.90+215.1%-82.1%$47.87M$192.35M-1.63770NEPHNephros3.3061 of 5 stars$4.28-0.8%$5.50+28.7%+160.2%$45.69M$14.16M35.4230WOKWORK Medical Technology GroupN/A$0.62-32.0%N/A-98.5%$45.43M$11.51M0.00226PSTVPlus Therapeutics2.9536 of 5 stars$0.41+1.0%$7.88+1,830.1%-66.6%$40.40M$5.82M-0.1820Gap UpMODDModular Medical1.0581 of 5 stars$0.720.0%N/A-69.1%$39.53MN/A-1.4020News Coverage Related Companies and Tools Related Companies PolyPid Alternatives Sensus Healthcare Alternatives Alpha Pro Tech Alternatives Fractyl Health Alternatives NeuroOne Medical Technologies Alternatives Zynex Alternatives Nephros Alternatives WORK Medical Technology Group Alternatives Plus Therapeutics Alternatives Modular Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTCY) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotricity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotricity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTCY Stock Alerts